Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd.

Primary objective: To evaluate the efficacy of different sequential therapies of clevudine (CLV) capsules versus entecavir (ETV) alone in the serological response [hepatitis B virus surface antigen (HBsAg) negative conversion rate and proportion of subjects with HBsAg decrease > 1 lg] in patients with chronic hepatitis B virus (HBV) infection who have been treated with nucleos(t)ide analogs (NAs). Secondary objectives: ① To evaluate the efficacy of different sequential therapies of CLV capsules compared with ETV monotherapy in other serological responses in patients with chronic HBV infection treated with NAs; ② To evaluate the efficacy of different sequential therapies of CLV capsules compared with ETV monotherapy in patients with chronic HBV infection treated with NAs; ③ To evaluate the efficacy of different sequential therapies of CLV capsules compared with ETV monotherapy in patients with chronic HBV infection treated with NAs; ④ To evaluate the efficacy of different sequential therapies of CLV capsules compared with ETV monotherapy in patients with chronic HBV infection treated with NAs in biochemical responses; ⑤ To evaluate the drug resistance of different sequential therapies of CLV capsules compared with ETV monotherapy in patients with chronic HBV infection treated with NAs; ⑥ To evaluate the safety of different sequential therapies of CLV capsules compared with ETV monotherapy in patients with chronic HBV infection treated with NAs.

To evaluate the efficacy and safety of Yiganmingmu oral liquid in the treatment of alcoholic fatty liver (liver and kidney deficiency syndrome) using placebo as control.

1. Through a dose escalation trial, observe the DLT and MTD of this product for patients with advanced solid tumors when the product is administered once a week by intravenous drip for 30 minutes, used for 2 consecutive weeks, and rested for 1 week, with each 3-week treatment cycle, so as to recommend a reasonable dosing regimen and basis for Phase II clinical studies; 2. Observe the pharmacokinetic (PK) characteristics of this product when administered intravenously. 3. Observe the frequency, duration and reversibility of adverse reactions of this product under the established dosing regimen. 4. Preliminary evaluation of the effectiveness of this product in patients with advanced solid tumors.